Canada has been grappling with the mpox Clade II virus since 2022; however, the nation has now confirmed its inaugural case of the mpox Clade I variant in a traveller who recently returned from Africa.
Canada has confirmed its first-ever case of the Mpox Clade I variant in a traveller from Manitoba, according to the latest reports from Canada’s Public Health Agency (PHAC). This individual is believed to have contracted the virus during a recent trip to central and eastern Africa, which he specifically reported upon his return. Upon landing back in Canada, the individual experienced symptoms reminiscent of mpox and promptly sought medical attention. Following examinations, tests were conducted by the National Microbiology Laboratory, which communicated the positive result to Manitoba health officials on November 22, as reported by PHAC.
This alarming development marks a new chapter in Canada’s ongoing battle against mpox, having first recorded cases in 2022, where it dealt exclusively with the Clade II variant. The initial case of mpox identified in Canada back in 2022 pertained to this Clade II variant, leading to various public health responses and increased awareness across the nation.
Mpox Still A Global Public Health Emergency; WHO
On Friday, the World Health Organization reiterated its classification of Monkeypox as a ‘Public Health Emergency of International Concern (PHEIC).’ The African continent continues to wage a significant battle against this viral disease, with over 46,000 suspected cases reported across several nations and more than 1,000 suspected fatalities. Among all, the Democratic Republic of Congo (DRC) has recorded the highest number of confirmed cases and deaths across the continent. The first declaration of mpox as a Global Health Emergency occurred in August 2024, coinciding with the onset of a severe outbreak that has since transcended borders. Most recently, Canada has reported its pioneering case of the Mpox Clade I variant amidst ongoing global concerns. Additionally, the WHO has recently authorized the use of Japanese mpox vaccines for children, aiming to enhance protective measures against the virus.
The PHAC has reassured the public, stating that the general population of Canada currently faces a low risk from this outbreak. Nonetheless, health officials are committed to active case monitoring, including contact tracing, to ensure that any potential spread of the virus is swiftly addressed and contained.
(With inputs from agencies)
Subscribe Now
## Interview with Dr. Sarah Thompson, Infectious Disease Specialist
## Interview with Dr. Sarah Thompson, Infectious Disease Specialist
**Editor:** Thank you for joining us today, Dr. Thompson. We’re discussing a significant development regarding mpox in Canada. Can you tell us more about the recently confirmed case of the mpox Clade I variant?
**Dr. Thompson:** Thank you for having me. Yes, it’s an important topic. Canada has indeed confirmed its first case of the mpox Clade I variant in a traveler from Manitoba who had recently returned from central and eastern Africa. This individual exhibited symptoms consistent with mpox and sought medical attention immediately upon returning to Canada. Testing was conducted by the National Microbiology Laboratory, which confirmed the infection.
**Editor:** This case marks a significant shift, as Canada has been dealing with mpox Clade II since 2022. What are the implications of this new Clade I variant?
**Dr. Thompson:** The emergence of the Clade I variant is concerning because it has historically been associated with a higher risk of severe illness compared to Clade II. While the majority of mpox cases result in full recovery, Clade I may have more serious health implications. It highlights the need for vigilance and robust health protocols to manage and contain the virus, particularly as it can be imported from regions where it is more prevalent.
**Editor:** How should travelers to regions where mpox is common protect themselves, and what should they do if they exhibit symptoms upon returning home?
**Dr. Thompson:** Travelers should educate themselves about ongoing outbreaks and take precautions such as avoiding close contact with sick individuals, practicing good hygiene, and possibly getting vaccinated if a vaccine is available. If someone returns home with symptoms like fever, rash, or other signs associated with mpox, they should seek medical attention immediately and inform the healthcare provider about their travel history. Early detection is key to managing the situation effectively.
**Editor:** What steps are health authorities taking in light of this new information to ensure public safety?
**Dr. Thompson:** Public health authorities, like Canada’s PHAC, are likely to increase surveillance and testing for new cases, especially among travelers returning from affected regions. They will also communicate guidelines to healthcare providers and the public, provide updates on vaccination availability, and encourage individuals to report any suspicious symptoms. Contact tracing may also be implemented to prevent further transmission.
**Editor:** Thank you, Dr. Thompson, for your insights. As always, it’s essential to stay informed and prepared in the face of evolving public health challenges.
**Dr. Thompson:** Thank you for having me. It’s crucial that we prioritize public health, and awareness is the first step.
